Table 1.
GA (n = 94) | IFN-β (n = 128) | Untreated (n = 141) | Adjusted P value* | |
---|---|---|---|---|
Female, n (%) | 68 (73) | 95 (74) | 117 (85) | 0.0344 |
Disease subtype (CIS/RR) | 7/87 | 9/119 | 32/109 | 0.0001 |
Symptom duration at sampling | 6.12 (6.36) | 6.65 (6.36) | 7.48 (8.06) | 0.5644 |
Age at first symptom | 34.23 (9.19) | 34.77 (9.30) | 33.35 (9.07) | 0.4841 |
BPF | 0.885 (0.034) | 0.871 (0.036) | 0.880 (0.040) | 0.0178 |
EDSS | 1.04 (1.01) | 1.19 (1.04) | 1.07 (1.09) | 0.5539 |
T2LV** | 3.19 (2.58) | 3.65 (2.64) | 3.93 (4.75) | 0.1720 |
Adjusted for symptom duration, age at first symptom, and gender (unless outcome of interest). MRI measurements were captured in a time window of 6 months before or after sampling.
P value from model with natural log transformation of T2 lesion volume value.